Posted 04 October, 2023

IR-Med, Inc. appointed new CEO

CEO Change detected for ticker OTC:IRME in a 8-K filed on 04 October, 2023.

  Effective as of October 15, 2023, the board of directors (the "Board") of IR-Med, Inc. (the "Company") appointed Mr. Tzur Di-Cori to serve as its Chief Executive Officer (CEO), effective October 15, 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IR-Med, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company was founded by Ronnie Klein and Yaniv Cohen in April 2007 and is headquartered in Rosh Haayin, Israel.
Market Cap
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of October 15, 2023, the board of directors (the "Board") of IR-Med, Inc. (the "Company") appointed Mr. Tzur Di-Cori to serve as its Chief Executive Officer (CEO), effective October 15, 2023. Mr. Di-Cori will also serve as the Chief Executive Officer of the Company's wholly-owned subsidiary, IR-Med LTD., an Israeli corporation.

Mr. Di-Cori, age 56, has served as the Co-Founder and owner at NatureIM Ltd. since 2023, a private holding company focused on developing peptide-derived materials for various purposes. From 2020-2023, Mr. Di-Cori served as CEO of DUSMIT Ltd., a privately-owned start-up company active in the health tech industry and agriculture which focuses on the development of air purification technology based on a real-time denaturation process, solving indoor air pollution. From 2017-2020, he served as Chief Executive Officer and co-founder at Veoli Ltd., a company which develops solutions for medical cannabis delivery. Prior to that, from 2014 to 2017, he served as Chief Executive Officer of Motorika Medical Ltd., a company developing robotic physical therapy devices for upper and lower extremities. From 2011 to 2014, Mr. Di-Cori served as President and CEO at LifeWatch Technologies Ltd., which was subsequently acquired and is currently owned by Koninklijke Philips N.V.

In conjunction with his appointment, the Company and Mr. Di-Cori entered into an employment agreement (the "Employment Agreement"), pursuant to which he will be subject to standard confidentiality, intellectual property assignment and non-compete provisions. In addition, in consideration of his service, Mr. Di-Cori will receive a monthly gross salary of NIS 45,000 ($11,842 approximately) and options to purchase 1,000,000 shares of the Company's common stock at an exercise price of $0.58 per share, subject to and in accordance with the terms and conditions of the Company's 2020 Incentive Stock Plan. The options shall vest over a four year period, with 25% of the options to vest on September 30, 2024, with the balance to vest in six (6) bi-annual installments, of sixteen point six percent (16.66%) shares from the remaining balance, every six months which shell vest starting at March 31, 2025, and thereafter at the end of each subsequent 6 months period, ending by September 30, 2027, provided that Mr. Di-Cori in still acting as the Chief Executive Officer of the Company.

No family relationships exist between Mr. Di-Cori and any of the Company's directors or other executive officers. There are no arrangements between Mr. Di-Cori and any other person pursuant to which Mr. Di-Cori was selected as an officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Di-Cori has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

A copy of the Employment Agreement is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The description of the employment terms of Mr. Di-Cori is a summary only and is qualified in its entirety by reference to Exhibit 10.1.